Avanir Pharmaceuticals, Inc.
is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.

Press Releases

Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer’s Disease
Nov 16, 2015
Avanir Pharmaceuticals Announces JAMA Publication of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation in...
Sep 22, 2015
Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026
Aug 11, 2015